MedPath

The effect of agnogl on oligomenorrhea in polycystic ovary syndrome

Phase 2
Conditions
Oligomenorrhea.
-
Registration Number
IRCT2015072623350N1
Lead Sponsor
Vice Chancellor for research, Hamadan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
120
Inclusion Criteria

being married; Being pregnant; There oligomenorrhea; No known physical or mental illness confirmed by a psychiatrist; Not taking any hormonal medication to treat menstrual disorders in the last three months; No history of allergies to herbal medicines; No drugs affecting the menstrual cycle; Not taking anti-androgen drugs and combinations of estrogen and progesterone secretion and insulin action and insulin and drugs affecting between 1 month before the survey; No history of liver disease, kidney, cardiovascular, diabetes Exclusion criteria: taking any medications that affect the menstrual cycle; Allergy medication; Drugs and oral contraceptives; Androgen-secreting tumors, high blood prolactin; Unwillingness to cooperate in the project

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improve oligomenorrhea. Timepoint: Before, 3 months after intervention. Method of measurement: Check list.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath